Christoph Gretler from Credit Suisse retains his positive opinion on the stock with a Buy rating. The target price has been revised upwards and is now set at EUR 100, compared with EUR 87 previously. | April 11, 2023
MorphoSys AG (NASDAQ:MOR) is a commercial-stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer.
Straumann Holding AG (OTCPK:SAUHF) Q3 2022 Results Conference Call November 02, 2022 5:30 AM ET Company Participants Guillaume Daniellot - CEO Peter Hackel - CFO Conference Call.